Indicated for the treatment of critical limb ischemia (CLI), the product is the first allogeneic cell therapy to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. The company has partnered with Mumbai based pharma company Cipla for the marketing and distribution of the product. BioSpectrum interacted with B N Manohar, Managing Director & Chief Executive Officer, Stempeutics Research, Bengaluru to find out more about this innovative product.
What are the key highlights of Stempeucel?
The key feature of Stempeucel is that it is an on-demand, cryo-preserved, allogeneic regenerative medicine targeting unmet needs. It is physician prescribed and the drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers for CLI treatment. There is a unique patented stem cell pooling technology involved. We have 57 filed patents for this product, 18 international patents granted for Stempeucel pooling technology, including United States, France, UK, Germany, Italy, China, Japan, Australia, New Zealand, Singapore, South Africa and Philippines. It is the first stem cell product with pooling technology to be classified as an Advanced Therapy Medicinal Product (ATMP) and granted Orphan Drug Designation by the European Medicines Agency (EMA) in 2015. Few other indications where this product is being explored includes an ongoing Phase 3 clinical trial for osteoarthritis and diabetic foot ulcer, ongoing Phase 1/2 study for perianal fistula due to Chron’s Disease indication; and we are starting Phase 2 COVID-19 acute respiratory distress syndrome (ARDS) study with the government support.
Please share more details about the CLI treatment procedure.
Diese Geschichte stammt aus der November 2020-Ausgabe von Bio Spectrum.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der November 2020-Ausgabe von Bio Spectrum.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Economic Survey Lays Focus On Mental Healthcare For The First Time
For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.